TABLE 2.
LncRNAs regulating NLRP3 inflammasome in diabetes complications.
| lncRNA | Expression | Target | Expression | Mechanism | Phenomenon | Diseases | Reference |
|---|---|---|---|---|---|---|---|
| Gm4419 | ↑ | NF-κB | activate | activates NF-κB pathway | MCs pyroptosis | DN | Yi et al. (2017) |
| ANRIL | ↑ | miR-497 | ↓ | ↑TXNIP, ↑NLRP3 | HK-2 pyroptosis | DN | Wang and Zhao, (2021) |
| Kcnq1ot1 | ↑ | miR-486a-3p | ↓ | ↑NLRP3 | podocyte pyroptosis | DN | Zhang et al. (2021) |
| MALAT1 | ↑ | miR-23c | ↓ | ↑ELAVL1, ↑NLRP3 | HK-2 pyroptosis | DN | Li et al. (2017a) |
| GAS5 | ↓ | miR-452-5p | ↓ | ↑NLRP3 | HK-2 pyroptosis | DN | Xie et al. (2019) |
| Kcnq1ot1 | ↑ | miR-506-3p | ↓ | ↑NLRP3 | HK-2 pyroptosis | DN | Zhu et al. (2020) |
| MALAT1 | ↑ | miR-200c | ↑ | ↑NRF2, ↑NLRP3 | podocyte pyroptosis | DN | Zuo et al. (2021) |
| MALAT1 | ↑ | miR-30c | ↓ | ↑NLRP3 | HK-2 pyroptosis | DN | Liu et al. (2020) |
| NEAT1 | ↑ | miR-34c | ↓ | ↑NLRP3 | HK-2 pyroptosis | DN | Zhan et al. (2020) |
| HCP5 | ↑ | miR-93-5p | ↓ | ↑HMGA2 ↑TNF-α, IL-6, IL-1β |
excessive proliferation, fibrosis and inflammation of MCs | DN | Wang et al. (2021a) |
| SNHG16 | ↑ | miR-146a-5p | ↓ | ↑IRAK1 activates NF-κB pathway | positively regulates proliferation, migration, and angiogenesis of hRMECs | DN | Cai et al. (2021) |
| SNHG16 | ↑ | miR-7-5p | ↓ | ↑IRS1 activates PI3K/AKT pathway | DN | Cai et al. (2021) | |
| MALAT1 | ↑ | p38 | — | activates ASK1/p38 pathway, ↑NLRP3 | positively regulates proliferation, migration, and angiogenesis of hRMECs | DR | Zou et al. (2021) |
| H19 | ↓ | miR-19b | ↑ | ↓SIRT1,↑TNF-α, IL-1β, IL-6 | negatively regulates inflammatory responses of ARPE-19 hRMECs | DR | Luo et al. (2021) |
| GAS5 | ↓ | miR-34b-3p | ↑ | ↓AHR, ↑NLRP3 | HL-1 cardiomyocytes pyroptosis | DCM | Xu et al. (2020) |
| MALAT1 | ↑ | miR-141 | ↓ | ↑NLRP3 | cardiac fibrosis | DCM | (Che et al., 2020c) |
| Kcnq1ot1 | ↑ | miR-214-3p | ↓ | ↑caspase-1, IL-1β | cardiac fibrosis | DCM | Yang et al. (2018) |
| GAS5 | ↑ | miR-21-5p | ↓ | activates TLR4/NF- κB pathway | AC16 cardiomyocytes pyroptosis | DCM | Zhao et al. (2020) |
| HCG18 | ↑ | miR-146a | ↓ | ↑TRAF6,↑TNF-α, IL-1β, IL-6 | M1 macrophage polarization | DPN | Ren et al. (2021) |
| PVT1 | ↑ | miR-146a | ↓ | activates TGF-β/SMAD4 pathway, ↑TNF-α, IL-1, IL-6 and TGF-β1 | promotes cartilage degradation | DOA | Wang et al. (2021b) |
NF-κB, nuclear factor kappa light-chain enhancer of activated B cells; MCs, mesangial cells; ANRIL, antisense noncoding RNA, in the INK4 locus; miR, miRNA; TXNIP, thioredoxin-interacting protein; HK-2, human renal tubular cells; Kcnq1ot1, Kcnq1 overlapping transcript 1; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; ELAVL1, ELAV-like RNA, binding protein 1; GAS5, growth arrest-specific 5; NRF2, nuclear factor erythroid-2-related factor 2; NEAT1, nuclear-enriched abundant transcript 1; HCP5, HLA, complex P5; HMGA2, high mobility group AT-hook 2; SNHG16, small nucleolar RNA, host gene 16; IRAK1, interleukin-1, receptor-associated kinase 1; IRS1, insulin receptor substrate 1; PI3K, phosphatidylinositol 3-kinase; hRMECs, human retinal microvascular endothelial cells; SIRT1, silence information regulator factor-related enzymes 1; ARPE-19, retinal pigment epithelial; AHR, aryl hydrocarbon receptor; TLR4, Toll-like receptor 4; HCG18, HLA, complex group 18; TRAF6, TNF, receptor associated factor 6; PVT1, plasmacytoma variant translocation 1; TGF-β1, transforming growth factor β1; SMAD4, mothers against decapentaplegic homolog 4; DN, diabetic nephropathy; DR, diabetic retinopathy; DCM, diabetic cardiomyopathy; DPN, diabetic peripheral neuropathy; DOA, diabetic osteoarthritis.